Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

NASH play Akero emerges from stealth with $65M

June 25, 2018 11:27 AM UTC

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis.

New investors Atlas Venture, venBio and Versant Ventures joined founding investor Apple Tree Partners as co-leaders in the round, announced Monday. Founded in 2017, Akero emerged from stealth mode with Monday's announcement...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article